{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:28:43Z","timestamp":1768217323938,"version":"3.49.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In real clinical practice, patients classified as microscopic polyangiitis (MPA) according to the new 2022 criteria, despite proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA) positivity, are occasionally encountered. Hence, this study investigated the clinical utility of PR3-ANCA detected at diagnosis in MPA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 191 patients with MPA in this study and retrospectively reviewed their medical records, in which clinical data at diagnosis and during follow-up were recorded. Additionally, we investigated three major poor complications of MPA, such as subsequent all-cause mortality (ACM), relapse, and end-stage kidney disease (ESKD). Cumulative survival rates were compared among the groups using Kaplan\u2013Meier survival analysis with the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At diagnosis, the median age of 191 MPA patients was 64 years (68 males and 123 females). PR3-ANCA was detected in only 10 patients (5.2%). During follow-up, among the 191 MPA patients, 32 patients died, 43 patients experienced subsequent relapse, and 39 progressed to ESKD. In the comparative analyses, at diagnosis, PR3-ANCA-positive MPA patients were younger and had lower white blood cell count and blood urea nitrogen levels than PR3-ANCA-negative patients. During follow-up, PR3-ANCA-positive MPA patients showed a higher frequency of subsequent relapse than PR3-ANCA-negative patients. Additionally, in Kaplan-Meier survival analysis, PR3-ANCA-positive MPA patients exhibited a significantly lower relapse-free survival rate than PR3-ANCA-negative patients over the follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, we found that PR3-ANCA positivity at diagnosis is significantly associated with subsequent relapse in patients with MPA during follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1745280","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:17:52Z","timestamp":1768205872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical utility of proteinase 3-antineutrophil cytoplasmic antibody at diagnosis in predicting subsequent relapse in patients with microscopic polyangiitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jang Woo","family":"Ha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oh Chan","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides.","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/annrheumdis-2013-203255","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?","volume":"72","author":"Millet","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3349\/ymj.2022.0435","article-title":"Comparison of the 2022 ACR\/EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis with previous criteria.","volume":"64","author":"Pyo","year":"2023","journal-title":"Yonsei Med J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"B6","first-page":"85","article-title":"The utility of the ACR\/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"36","author":"Yoo","year":"2018","journal-title":"Clin Exp Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis.","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis.","volume":"81","author":"Robson","year":"","journal-title":"Ann Rheum Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/S2665-9913(24)00035-3","article-title":"Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"6","author":"Falde","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1016\/S2665-9913(24)00025-0","article-title":"Myeloperoxidase-specific antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"6","author":"Arnold","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3390\/diagnostics14171849","article-title":"Relapse predictors in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.","volume":"14","author":"Wawrzycka-Adamczyk","year":"2024","journal-title":"Diagnostics."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3904\/kjim.2021.043","article-title":"Clinical impact of proteinase 3-antineutrophil cytoplasmic antibody positivity in eosinophilic granulomatosis with polyangiitis.","volume":"37","author":"Ahn","year":"2022","journal-title":"Korean J Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/1756-185X.12926","article-title":"Antineutrophil cytoplasmic antibody (ANCA) testing: audit from a clinical immunology laboratory.","volume":"20","author":"Phatak","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"102618","DOI":"10.1016\/j.autrev.2020.102618","article-title":"2020 international consensus on ANCA testing beyond systemic vasculitis.","volume":"19","author":"Moiseev","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the birmingham vasculitis activity score (version 3).","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort.","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine."},{"key":"B19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMra2206346","article-title":"Humoral innate immunity and acute-phase proteins.","volume":"388","author":"Mantovani","year":"2023","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/rheumatology\/kez589","article-title":"All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type.","volume":"59","author":"Wallace","year":"2020","journal-title":"Rheumatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American college of rheumatology\/Vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease.","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3349\/ymj.2024.0512","article-title":"Is chest imaging alone adequate for diagnosing interstitial lung disease in microscopic polyangiitis based on the 2022 criteria?","volume":"66","author":"Do","year":"2025","journal-title":"Yonsei Med J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis.","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1745280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:17:53Z","timestamp":1768205873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1745280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":27,"alternative-id":["10.3389\/fmed.2025.1745280"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1745280","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1745280"}}